Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elenbecestat PK/PD Bridging Study in Healthy Japanese and White Subjects
NCT02207790Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of elenbecestat in Alzheimer's disease (AD) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 9 more. Started Jul 2014; status: completed.
02
Drugs
elenbecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02207790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207790.